Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
$273.20-0.73%
Close 2026-10-30 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
Research Workspace
Put JNJ beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS reaches at least $11.55 in 2026: Comparison needs review.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 41% growth a year, above the roughly 7% analysts expect, leaving little room for error.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskJNJ’s case rests on durable healthcare growth, though its revenue growth has slowed across recent quarters. Q3 revenue grew 5.9% year over year, and adjusted EPS beat estimates by 2.4%. JNJ trades at 26× P/E versus a 16× peer median, and 24× its own history. The market is pricing in more growth than we forecast, leaving expectations full. Our model puts the next-quarter miss probability near 12%. The comparison behind the 2026 EPS pillar needs review. Peer multiples imply a price about 41% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. JNJ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering JNJ (as of Oct 2026).
Based on 16 Wall Street analysts offering 12-month price targets for JNJ in the last 4 months.
Continue this research
Compare JNJ with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| JNJ Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put JNJ next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance innovation and pipeline progress in priority disease areas
Official Phase 1 data advance pipeline development, but early-stage results have limited thesis impact.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $273.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $273.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance innovation and pipeline progress in priority disease areas
Study cohort results provide incremental evidence on pipeline progress; clinical and commercial significance is unspecified.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
New U.S. coronary catheter modestly expands J&J's device portfolio.
Advances: Increase 2026 revenue guidance to $101.1B
Coverage highlights a raised sales outlook supporting the 2026 growth objective.
Increase 2026 revenue guidance to $101.1B
Earnings-call coverage flags MedTech challenges alongside growth outlook.
Increase 2026 revenue guidance to $101.1B
Earnings-call transcript is relevant, but headline supplies no distinct thesis-changing detail.
Advances: Increase 2026 revenue guidance to $101.1B
Raised sales outlook supports growth, though midpoint remains below the tracked $101.1B target.
Talc-resolution impact and slower MedTech growth create earnings and execution headwinds.
